We describe a new, water-soluble formulation of levodopa plus benserazide (Madopar LIQ) for the treatment of Parkinson's disease. Two dosage strengths are available: 100 mg levodopa plus 25 mg benserazide and 50 mg levodopa plus 12.5 mg benserazide. Pharmacokinetic data show that levodopa absorption is more rapid than with standard Madopar, resulting in a shorter time to peak plasma concentration. Other pharmacokinetic values are comparable to those obtained with the standard formulation. We discuss the clinical advantages of this new water-soluble formulation, particularly when the patient requires rapid onset of action for morning or circadian akinesia. The indications of this formulation in patients with dysphagia and in other clinical situations, e.g. during the postoperative period and for levodopa dosage adjustment in ambulatory care, are discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of DOPA decarboxylase inhibitor supplements on the incidence of urinary tract infections in Parkinson's disease patients: A systematic review and meta-analysis of randomized controlled trials.
Arch Ital Urol Androl
October 2024
Department of Urology, School of Medicine, Ibb University.
Objectives: Parkinson's disease is the most common neurodegenerative disease. Combining levodopa with other drugs, including decarboxylase inhibitors (DCI) is its most effective treatment. Urinary tract infection (UTI) is the most common cause of hospitalization in Parkinson's patients, making it crucial to find an appropriate treatment to reduce the incidence of this complication.
View Article and Find Full Text PDFThe Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.
Actas Esp Psiquiatr
December 2024
Department of Neurology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, 210003 Nanjing, Jiangsu, China.
Background: Parkinson's disease (PD), a prevalent neurological condition, is characterized by the progressive degeneration of dopamine-producing neurons, leading to motor dysfunction and non-motor symptoms. Therefore, this study aimed to evaluate the impact of combining levodopa/benserazide with pramipexole on PD patients, focusing on cognitive function, plasma monoamine neurotransmitter levels, and serum growth differentiation factor-15 (GDF-15) and angiopoietin-1 (Ang-1) levels.
Methods: This retrospective study included 120 PD patients admitted to the hospital between January 2021 and January 2023.
Respiratory Alkalosis as an Adverse Effect of Safinamide?
Eur J Case Rep Intern Med
October 2024
Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal.
Unlabelled: Respiratory alkalosis is associated with central nervous system (CNS) diseases, drugs, lung diseases and others. Safinamide is a recent anti-parkinsonian drug with anti-dyskinetic properties and a good adjunct to L-dopa therapy during the activation period, with no significant adverse effects described. The authors present a case of a 71-year-old woman, with Parkinson's disease treated with levodopa/benserazide, safinamide, amitriptyline, sertraline and diazepam.
View Article and Find Full Text PDFMulticolorimetric Sensor Array Based on Silver Metallization of Gold Nanorods for Discriminating Dopaminergic Agents.
ACS Chem Neurosci
October 2024
Department of Chemistry, Sharif University of Technology, Tehran 111559516, Iran.
Dopaminergic agents are compounds that modulate dopamine-related activity in the brain and peripheral nerves within the pathways on both sides of the blood-brain barrier. Atypical levels of them can precipitate a multitude of neurological disorders, whose timely diagnosis signifies not only stopping the advancement of the illness but also surmounting it. A silver metallized gold nanorod (AuNRs) conditional sensor array, designed to detect dopaminergic agents for assessing nervous system disorders, yielded significant results in simultaneous detection and discrimination of Benserazide (Benz), Levodopa (L-DOPA), and Carbidopa (Carb).
View Article and Find Full Text PDFBenserazide is neuroprotective and improves functional recovery after experimental ischemic stroke by altering the immune response.
Sci Rep
August 2024
Neuroscience Center, HiLIFE, University of Helsinki, P.O. Box 63, 00014, Helsinki, Finland.
Stroke is a leading cause of permanent disability worldwide. Despite intensive research over the last decades, key anti-inflammatory strategies that have proven beneficial in pre-clinical animal models have often failed in translation. The importance of neutrophils as pro- and anti-inflammatory peripheral immune cells has often been overlooked in ischemic stroke.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!